These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18839139)

  • 1. Science, medicine and industry: are we getting out of the black hole in sepsis research?
    Suter PM; Takala J
    Intensive Care Med; 2008 Nov; 34(11):1950-4. PubMed ID: 18839139
    [No Abstract]   [Full Text] [Related]  

  • 2. Once is not enough: clinical trials in sepsis.
    Sweeney DA; Danner RL; Eichacker PQ; Natanson C
    Intensive Care Med; 2008 Nov; 34(11):1955-60. PubMed ID: 18839140
    [No Abstract]   [Full Text] [Related]  

  • 3. Editors' comments on a new trial of activated protein C for persistent septic shock.
    Mancebo J; Antonelli M
    Intensive Care Med; 2008 Nov; 34(11):1948-9. PubMed ID: 18839138
    [No Abstract]   [Full Text] [Related]  

  • 4. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.
    Finfer S; Ranieri VM; Thompson BT; Barie PS; Dhainaut JF; Douglas IS; Gårdlund B; Marshall JC; Rhodes A
    Intensive Care Med; 2008 Nov; 34(11):1935-47. PubMed ID: 18839141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PROWESS--milestone in lowering sepsis mortality].
    Reinhart K
    Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016
    [No Abstract]   [Full Text] [Related]  

  • 6. "All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock.
    Barie PS
    Surg Infect (Larchmt); 2007 Oct; 8(5):491-4. PubMed ID: 17999581
    [No Abstract]   [Full Text] [Related]  

  • 7. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 8. [Endogenous anticoagulant therapy for sepsis. Success and failure].
    Wiedermann CJ
    Internist (Berl); 2007 May; 48(5):537-42, 544. PubMed ID: 17390117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated protein C and septic shock: a propensity-matched cohort study*.
    Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
    Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is industry guiding the sepsis guidelines? A perspective.
    Durbin CG
    Crit Care Med; 2007 Mar; 35(3):689-91. PubMed ID: 17255867
    [No Abstract]   [Full Text] [Related]  

  • 11. [Sepsis therapy -- how effective are the therapy strategies?].
    Brunkhorst F; Reinhart K
    Chirurg; 2008 Sep; 79(9):877-8. PubMed ID: 18942197
    [No Abstract]   [Full Text] [Related]  

  • 12. Prowess-shock trial: a protocol overview and perspectives.
    Silva E; de Figueiredo LF; Colombari F
    Shock; 2010 Sep; 34 Suppl 1():48-53. PubMed ID: 20523271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioethics, the Surviving Sepsis Campaign and the industry.
    Bion J; Vincent JL; Angood P
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):63. PubMed ID: 16489529
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioethics, the Surviving Sepsis Campaign, and the industry.
    Wiedermann CJ
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):442-4. PubMed ID: 16091869
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
    Röggla G; Moser B
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):65. PubMed ID: 16612881
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
    Ricevuti G; Gasparetto C
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):64-5. PubMed ID: 16612880
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
    Mackenzie AF
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):64. PubMed ID: 16612879
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
    Malliani A
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):63-4. PubMed ID: 16612878
    [No Abstract]   [Full Text] [Related]  

  • 19. [Activated protein C in patients with septic shock: contra].
    Graf J
    Dtsch Med Wochenschr; 2010 Nov; 135(47):2371. PubMed ID: 21082531
    [No Abstract]   [Full Text] [Related]  

  • 20. Xigris is withdrawn from the market. A 10 year odyssey.
    Suter PM
    Minerva Anestesiol; 2011 Dec; 77(12):1128-9. PubMed ID: 22134426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.